Published in Oncotarget on November 01, 2013
Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 3.54
The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev (2015) 2.28
Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res (2014) 1.75
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget (2015) 1.06
The bromodomain: from epigenome reader to druggable target. Biochim Biophys Acta (2014) 1.02
Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget (2014) 1.02
The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J Biol Chem (2014) 0.90
Targeting bet bromodomain proteins in solid tumors. Oncotarget (2016) 0.89
Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget (2016) 0.87
An epigenetic gateway to brain tumor cell identity. Nat Neurosci (2015) 0.85
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Cureus (2016) 0.85
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors. Oncotarget (2015) 0.82
Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Oncotarget (2016) 0.81
Regulation of prostate cancer progression by the tumor microenvironment. Cancer Lett (2016) 0.81
BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells. Stem Cell Res Ther (2016) 0.79
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget (2015) 0.78
MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocr Relat Cancer (2016) 0.78
Twist-BRD4 complex: potential drug target for basal-like breast cancer. Curr Pharm Des (2015) 0.78
The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma. PLoS One (2015) 0.78
The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int J Mol Sci (2016) 0.77
Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4. Sci Rep (2015) 0.76
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget (2016) 0.76
Bromodomains: Translating the words of lysine acetylation into myelin injury and repair. Neurosci Lett (2015) 0.76
Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells. Oncotarget (2016) 0.75
A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers. Yale J Biol Med (2017) 0.75
Targeting tachykinin receptors in neuroblastoma. Oncotarget (2016) 0.75
Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis. Oncotarget (2016) 0.75
MYCN-targeting vaccines and immunotherapeutics. Hum Vaccin Immunother (2016) 0.75
Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells. Oncotarget (2017) 0.75
Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises. Cancer Genomics Proteomics (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
The language of covalent histone modifications. Nature (2000) 44.92
Selective inhibition of BET bromodomains. Nature (2010) 18.79
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Elongation by RNA polymerase II: the short and long of it. Genes Dev (2004) 9.17
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics (2006) 6.50
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem (2007) 5.06
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol Cell Biol (2007) 3.95
Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol Biol Cell (2009) 3.29
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell (2008) 3.05
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol (2009) 3.01
The requirement for cyclin D function in tumor maintenance. Cancer Cell (2012) 2.49
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
Negative autoregulation of c-myc transcription. EMBO J (1990) 2.38
You bet-cha: a novel family of transcriptional regulators. Front Biosci (2001) 2.20
The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet (2012) 2.13
Adult medulloblastoma comprises three major molecular variants. J Clin Oncol (2011) 2.07
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol (2010) 2.04
Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer (2004) 2.00
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res (2013) 1.84
Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A (2012) 1.65
Challenging issues in pediatric oncology. Nat Rev Clin Oncol (2011) 1.56
The repair and signaling responses to DNA double-strand breaks. Adv Genet (2013) 1.48
Identification and characterization of BRDT: A testis-specific gene related to the bromodomain genes RING3 and Drosophila fsh. Genomics (1997) 1.43
P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle (2007) 1.39
Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol (2002) 1.38
MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One (2011) 1.38
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med (2012) 1.28
Cytogenetics and molecular genetics of childhood brain tumors. Neuro Oncol (1999) 1.06
Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. Oncogene (2009) 1.02
MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neuro Oncol (2002) 0.99
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol (2012) 0.97
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. J Neurooncol (2012) 0.95
c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients. BMC Cancer (2011) 0.92
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol (2002) 82.19
qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol (2007) 16.15
Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med (2008) 10.88
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol (2009) 6.25
Elimination of primer-dimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem (2002) 4.54
Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet (2003) 4.44
Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet (2004) 4.09
Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell (2009) 3.92
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res (2003) 3.06
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res (2008) 2.71
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
Rapid detection of VHL exon deletions using real-time quantitative PCR. Lab Invest (2005) 2.61
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell (2010) 2.38
Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am (2008) 2.24
Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol (2009) 2.21
Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am (2010) 2.21
Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood (2003) 2.13
RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res (2006) 2.11
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst (2009) 2.09
Molecular karyotyping: array CGH quality criteria for constitutional genetic diagnosis. J Histochem Cytochem (2005) 2.05
A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet (2008) 2.02
Cavernoma-related epilepsy: review and recommendations for management--report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2013) 2.00
A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet (2011) 1.99
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
RTPrimerDB: the portal for real-time PCR primers and probes. Nucleic Acids Res (2008) 1.95
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat Cell Biol (2012) 1.89
Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res (2002) 1.84
Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol (2005) 1.82
Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res (2010) 1.81
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res (2010) 1.77
Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol (2002) 1.73
arrayCGHbase: an analysis platform for comparative genomic hybridization microarrays. BMC Bioinformatics (2005) 1.71
A novel gene family NBPF: intricate structure generated by gene duplications during primate evolution. Mol Biol Evol (2005) 1.71
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68
Computer-assisted secondary reconstruction of unilateral posttraumatic orbital deformity. Plast Reconstr Surg (2002) 1.64
Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene (2005) 1.62
Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci U S A (2010) 1.61
Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood (2013) 1.59
The need for transparency and good practices in the qPCR literature. Nat Methods (2013) 1.58
Guidelines for molecular karyotyping in constitutional genetic diagnosis. Eur J Hum Genet (2007) 1.56
Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One (2009) 1.55
Cerebral cavernomas in the adult. Review of the literature and analysis of 72 surgically treated patients. Neurosurg Rev (2002) 1.53
Molecular classification of low-grade diffuse gliomas. Am J Pathol (2010) 1.51
Delineation of a critical region on chromosome 18 for the del(18)(q12.2q21.1) syndrome. Am J Med Genet A (2008) 1.49
A new system for computer-aided preoperative planning and intraoperative navigation during corrective jaw surgery. IEEE Trans Inf Technol Biomed (2007) 1.48
ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood (2003) 1.47
Novel cryptic chromosomal rearrangements in childhood acute lymphoblastic leukemia detected by multiple color fluorescent in situ hybridization. Haematologica (2005) 1.47
Effective surgical treatment of cerebral cavernous malformations: a multicenter study of 79 pediatric patients. J Neurosurg Pediatr (2011) 1.45
Smoothing waves in array CGH tumor profiles. Bioinformatics (2009) 1.45
Measurable impact of RNA quality on gene expression results from quantitative PCR. Nucleic Acids Res (2011) 1.45
Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol (2006) 1.44
CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer (2011) 1.44
Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol (2010) 1.43
Carotid artery stenting: do procedural complications relate to the side intervened upon?: results from the Carotid Artery Stent (CAS)-Registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). Catheter Cardiovasc Interv (2009) 1.43
The microRNA body map: dissecting microRNA function through integrative genomics. Nucleic Acids Res (2011) 1.41
Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res (2006) 1.40
MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One (2011) 1.38
Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis (2005) 1.34
Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am J Hum Genet (2007) 1.33
Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer (2010) 1.32
Disease-causing 7.4 kb cis-regulatory deletion disrupting conserved non-coding sequences and their interaction with the FOXL2 promotor: implications for mutation screening. PLoS Genet (2009) 1.32
Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. Hum Mutat (2008) 1.31
Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat (2006) 1.29
Challenges for CNV interpretation in clinical molecular karyotyping: lessons learned from a 1001 sample experience. Eur J Med Genet (2009) 1.29